The deal with pharmaceutical company Laxisam is one of several agreed by the Russian Direct Investment Fund in recent weeks to supply the vaccine, which is currently being tested in a large-scale trial in Moscow.

It has also made supply deals with Kazakhstan, India, Mexico and two Brazilian states.

The Guardian

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.